Recurrence · Adults with oral cavity or oropharyngeal cancer
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Adverse events: severe acute effects in both groups (subcutaneous fibrosis, telangiectasia, moderate-to-severe oedema, xerostomia, trismus, dysphagia); subcutaneous fibrosis more prevalent with surgery + radiotherapy…
1 study · 35 participants
Very low
Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Lower total dose radiotherapy (67.2 Gy over 5.6 weeks) showed no clear difference in locoregional control compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.
1 finding from 1 review
HR 1.13 [0.78, 1.64]
1 study
GRADE not reported
Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Lower total dose radiotherapy (67.2 Gy over 5.6 weeks) showed no clear difference in total mortality compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.
1 finding from 1 review
HR 1.38 [0.83, 2.29]
1 study
GRADE not reported
Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
1 finding from 1 review
Hyperfractionated/accelerated split course vs accelerated boost (Fu 1995, feasibility study, 75 participants): authors report no significant difference in total mortality; data not presented in a way that allows…
1 study · 75 participants
GRADE not reported
Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Higher total dose radiotherapy (76.8 Gy over 6.4 weeks) showed no clear difference in total mortality compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.
1 finding from 1 review
HR 1.08 [0.69, 1.70]
1 study
GRADE not reported
Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Hyperfractionated/accelerated/split-course radiotherapy showed no clear difference in total mortality compared with conventional (standard) fractionation radiotherapy; GRADE not reported.
1 finding from 1 review
Disease-free survival · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
1 finding from 1 review
Hyperfractionated/accelerated/split vs conventional, disease free survival: two trials (Fu 2000, Olmi 2003); results contradictory with substantial statistical heterogeneity (P = 0.02, I2 = 82%); no pooled estimate…
2 studies
GRADE not reported
Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
1 finding from 1 review
Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Higher total dose radiotherapy (76.8 Gy over 6.4 weeks) showed no clear difference in locoregional control compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.
1 finding from 1 review
HR 0.78 [0.55, 1.11]
1 study
GRADE not reported
Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Hyperfractionated/accelerated/split-course radiotherapy showed no clear difference in locoregional control compared with conventional (standard) fractionation radiotherapy; GRADE not reported.
1 finding from 1 review
Disease-free survival · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
1 finding from 1 review
Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
1 finding from 1 review
Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
1 finding from 1 review
Disease-free survival · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
1 finding from 1 review
Accelerated vs conventional, disease free survival: both trials reported this, but substantial clinical and statistical heterogeneity (P = 0.0004, I2 = 92%) meant a pooled analysis was not reported (Analysis 1.3).
2 studies
GRADE not reported
All‐cause mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
It is very uncertain whether altered fractionation radiotherapy (hyperfractionated and/or… changes mortality compared with conventional (standard) fractionation radiotherapy (very low certainty).
2 findings from 1 review
Disease-free survival · Adults with oral cavity or oropharyngeal cancer
The review found no eligible studies for this question.
1 finding from 1 review
Total mortality · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Total mortality: study reported survival significantly better with surgery and RT vs chemoradiotherapy, but no useable data; 32 participants (1 RCT, Iyer 2015 oral cavity subgroup).
1 study · 32 participants
Very low
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
The review found no eligible studies for this question.
1 finding from 1 review
Recurrence · Adults with oral cavity or oropharyngeal cancer
The review found no eligible studies for this question.
1 finding from 1 review